ESR1 and hepatocellular carcinoma: Importantly, since estrogen receptors (ER) are known to be present in advanced HCC, the therapeutic use of an estradiol-analogons, such as 2ME2, for antineoplastic/antiangiogenic therapy is unknown [26-28].